Immunoaugmenting therapeutics: Recombinant cytokines and biological response modifiers

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Immunotherapy has a long history in the treatment of cancer. Immunoaugmenting drugs were popularized by William B. Coley, who treated cancer patients with mixed bacterial toxins early in the 20th century.1 These early studies resulted in the clinical approval of microbially derived substances such as Bacille Calmette-Guerin (BCG) (bladder cancer, USA), Krestin, Picibanil, and Lentinan (gastric and other cancers, Japan), and Biostim and Broncho-Vaxom (recurrent infections, Europe). While these “crude” drugs have numerous immune augmenting activities, they also have regulatory difficulties due to impurities, lot-to-lot variability, and adverse side effects. Similarly, traditional herbal medicines (Asia) may contain constituents with immunotherapeutic activity. The purification, characterization, and synthetic production of active moieties from natural products (Bestatin, Taxol) and culture supernatants (FK-506, Rapamycin, Deoxyspergualin, and Cyclosporin) have provided valuable drugs. The current developmental focus is on recombinant proteins (cytokines and monoclonal antibodies (mAbs)), although the utility of these drugs are limited due, in part, to bioactivity and pharmacologic deficiencies (see chapter 8 of this volume for a discussion of cytokines and monoclonal antibodies as therapeutic agents).

Original languageEnglish (US)
Title of host publicationImmunotoxicology and Immunopharmacology, Third Edition
PublisherCRC Press
Pages143-170
Number of pages28
ISBN (Electronic)9781420005448
ISBN (Print)9780849337901
StatePublished - Jan 1 2006

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'Immunoaugmenting therapeutics: Recombinant cytokines and biological response modifiers'. Together they form a unique fingerprint.

Cite this